创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

胃复春联合替普瑞酮治疗对慢性萎缩性胃炎伴肠上皮化生患者的效果观察

Observation on Effect of Weifuchun Combined with Teprenone on Patients with Chronic Atrophic Gastritis and Intestinal Metaplasia

  • 摘要: 目的 观察胃复春联合替普瑞酮治疗对慢性萎缩性胃炎(chronic atrophic gastritis,CAG)伴肠上皮化生(intestinalmetaplasia,IM)患者胃镜积分和血清炎症因子的影响。方法 选择2020年1月至2023年1月期间在金华文荣医院诊治的80例CAG伴IM患者的临床资料,根据抛掷硬币法随机分为对照组和观察组,每组40例。对照组使用替普瑞酮胶囊,观察组在对照组的基础上联合胃复春片治疗,两组均连续治疗3个月。比较两组的临床疗效、中医证候积分、胃镜积分和血清指标。结果 治疗3个月后,观察组的治疗总有效率明显高于对照组(P < 0.05)。治疗3个月后,两组胃胀胃痛、嗳气、头晕乏力、食欲不振4项中医证候积分和胃镜积分下降,促胃液素(gastrin,GAS)、生长抑素(somatostatin,SOM)水平升高,肿瘤坏死因子α(tumornecrosis factor α,TNF-α)、白介素-8(interleukin-8,IL-8)水平降低(双侧P < 0.05),且观察组的以上指标优于对照组(单侧P < 0.025)。结论 胃复春片联合替普瑞酮胶囊治疗能有效缓解CAG伴IM患者的临床疗效,改善临床症状和胃镜积分,改善胃黏膜病理形态,缓解炎症反应。

     

    Abstract: Objective The present study aimed to observe the effect of Weifuchun combined with teprenone on gastroscopy scores and serum inflammatory factors in patients with chronic atrophic gastritis (CAG) accompanied by intestinal metaplasia (IM). Methods The clinical data of 80 patients with CAG and IM diagnosed and treated in Jinhua Wenrong Hospital from January 2020 to January 2023 were selected. They were randomly divided into the observation group and the control group, with 40 patients in each group and all patients being treated for 3 months. The control group was treated with teprenone capsules, and the observation group was treated with Weifuchun tablets on the basis of the control group. Clinical efficacy, traditional Chinese medical symptom scores, gastroscopy scores and serum indicators in both groups were compared. Results After 3 months of treatment, the total effective rate of the observation group was significantly higher than that of the control group (P < 0.05). After 3 months of treatment, the scores of four traditional Chinese medical syndromes, including bloating/ stomachache, belching, dizziness, and loss of appetite, as well as gastroscopy scores, decreased in both groups. The levels of gastrin (GAS) and somatostatin (SOM) increased, while the levels of tumor necrosis factor alpha (TNF-α) and interleukin-8 (IL-8) decreased (two-sided P < 0.05). After 3 months of treatment, the above indicators in the observation group were better than those in the control group (one-sided P < 0.025). Conclusion This study confirms that the combined treatment of Weifuchun tablets and teprenone capsules can effectively improve clinical efficacy and pathological morphology of gastric mucosa in patients with CAG and IM, and alleviate inflammatory reactions.

     

/

返回文章
返回